Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis

Journal of Experimental Medicine

Volumn 196, Issue 1, 2002, Pages 77-85

  Ji, Hong ^a,b   Pettit, Allison ^c   Ohmura, Koichiro ^a   Ortiz Lopez, Adriana ^a   Duchatelle, Veronique ^d   Degott, Claude ^d   Gravallese, Ellen ^c   Mathis, Diane ^a,b,e   Benoist, Christophe ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

^d BEAUJON HOSPITAL   (France)

^e JOSLIN DIABETES CENTER   (United States)

Author keywords

Cytokine; Inflammatory; Knockout; TNF; Transgenic

Indexed keywords

ANTIBODY; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE EROSION; CONTROLLED STUDY; HEREDITY; HUMAN; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ARTHRITIS, EXPERIMENTAL; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; IMMUNIZATION, PASSIVE; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TARSUS, ANIMAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036645277     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20020439     Document Type: Article

References (54)

1. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
2. Cell-cell interactions in synovitis: Antigen presenting cells and T cell interaction in rheumatoid arthritis
3. How important are T cells in chronic rheumatoid synovitis?
4. Anti-cytokine therapy in chronic destructive arthritis
5. Organ-specific disease provoked by systemic autoreactivity
6. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins
7. The arthritogenic T cell receptor and its ligand in a spontaneous model of arthritis
8. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme
9. Genetic influences on the end-stage effector phase of arthritis
10. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease
11. Arthritis critically dependent on innate immune system players
12. Autoantibodies to GPI in rheumatoid arthritis: Linkage between an animal model and human disease
13. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis
14. Impaired immune and acute-phase responses in interleukin-6-deficient mice
15. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1
16. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice
17. Immune and inflammatory responses in TNF-αdeficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response
18. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin
19. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
20. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice
21. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
22. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA
23. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
24. Gp130 and the interleukin-6 family of cytokines
25. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
26. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
27. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity
28. Defective inflammatory response in interleukin 6-deficient mice
29. Interleukin 6 plays a key role in the development of antigen-induced arthritis
30. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
31. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice
32. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice
33. Amelioration of established murine collagen induced arthritis with anti-IL-1 treatment
34. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice
35. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNF-α, anti-IL-Iα/β, and IL-1ra
36. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
37. Role of cytokines in rheumatoid arthritis
38. Constitutive intraarticular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis
39. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice
40. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
41. AntiTNF ameliorates joint disease in murine collagen induced arthritis
42. Influence of a recombinant human soluble TNF receptor Fc fusion protein on type II collagen induced arthritis in mice
43. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
44. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF-β, and others
45. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: Identification of a novel in vivo role for p75
46. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF
47. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
48. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption
49. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
50. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
51. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis
52. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts
53. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group
54. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis